Latest Growth Investment News

Acusensus Limited reported a robust FY25 with 20% revenue growth and a significant 84% jump in total contract value, setting the stage for an ambitious FY26 forecast of up to 41% revenue increase.

Acrow Limited reports a record FY25 with sales up 23%, driven by an 83% jump in its Industrial Access division, now half of group revenue. Despite soft formwork markets, strategic acquisitions and growth initiatives underpin a confident outlook.

Supply Network Limited reported a robust 15.5% revenue increase to $349.9 million and a 21.2% rise in profit after tax to $40 million for FY2025, alongside a higher fully franked final dividend of 38 cents per share.

GTN Limited reported a modest revenue decline and a sharper EBITDA drop in FY25 but rewarded shareholders with strong returns including dividends, buybacks, and a significant capital return.

Ansell Limited reported record FY25 sales and EBIT margins, completing KBU integration ahead of schedule and upgrading synergy targets. The company guides higher adjusted EPS for FY26, fully offsetting US tariff hikes through pricing.

WAM Income Maximiser Limited has reported a profitable first half since its April 2025 IPO, declaring its inaugural fully franked monthly dividend and setting guidance for dividend growth. The company’s diversified portfolio of ASX300 equities and investment grade corporate debt has delivered promising returns, underpinning its income and capital growth objectives.

Cobram Estate Olives Limited has reported record financial results for FY2025, driven by strong sales growth in Australia and a doubling of branded sales in the USA. The company is shifting its capital expenditure focus to expand its Californian operations while maintaining sustainable growth in Australia.

Aspen Group Limited reported a robust 18% increase in profit after tax to $57 million for FY25, driven by growth in both rental and development segments alongside strategic debt reduction and a $74 million equity raise.

Medical Developments International has reported a remarkable turnaround in FY25, posting a net profit after tax and securing paediatric approval for its flagship product Penthrox in Europe.

Medical Developments International Ltd reported an 18% increase in revenue to $39.1 million for FY25, returning to profitability with a net profit after tax of $0.1 million. The company advanced its Penthrox market expansion through regulatory approvals and new partnerships.

Medical Developments International reports a strong FY25 with significant margin gains and strategic progress, setting the stage for accelerated Penthrox expansion in FY26.

Whitehaven Coal reported a robust FY25 with $1.4 billion underlying EBITDA and strong production growth from Queensland acquisitions, maintaining a solid balance sheet and setting ambitious cost-saving targets for FY26.